Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
“While we’ve been focused on a 2017 close, it’s now clear that closing in early 2018 is more likely, and we’re quite comfortable with this timeline,” the spokesman said.
